Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2693326 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL2693319 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL2691303 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL7191976 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL8384596 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL23921599 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL10389540 | 0.95 | CHRM2 (0.43) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL27265137 | 0.95 | CHRM2 (0.43) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL262052 | 0.95 | CHRM2 (0.43) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL12948024 | 0.95 | CHRM2 (0.43) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295798-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2025-09-25 | — | — | US | disclosed |
| EP-4594327-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BeiGene Switzerland GmbH (CH) | 2025-08-06 | — | — | EP | disclosed |
| CN-119948031-A | Ligand-drug conjugates of isatecan analogs and medical uses thereof | 广州百济神州生物制药有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240376059-A1 | Compounds for the Treatment of Alzheimer's Disease | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2024-11-14 | — | — | US | disclosed |
| WO-2024067811-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BEIGENE, LTD. (KY) | 2024-04-04 | — | — | WO | disclosed |
| US-11939302-B2 | Compounds for the treatment of Alzheimer's disease | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2024-03-26 | — | — | US | disclosed |
| WO-2024057013-A1 | NLRP3 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| CN-117447359-A | Preparation method of high-purity peramivir intermediate | 浙江诚意药业股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117250295-A | Detection method of peramivir intermediate | 浙江诚意药业股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230302162-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-09-28 | — | — | US | disclosed |
| US-6077958-A | Heteroaromatic diphosphines as chiral ligands | ITALFARMACO SUD S.P.A. (IT) | 2000-06-20 | — | — | US | disclosed |
| EP-0770085-B1 | HETEROAROMATIC DIPHOSPHINES AS CHIRAL LIGANDS | CHEMI SPA (IT) | 1999-09-22 | — | — | EP | disclosed |
| US-5907045-A | Heteroaromatic diphosphines as chiral ligands | ITALFARMACO SUD S.P.A. (IT) | 1999-05-25 | — | — | US | disclosed |
| EP-0738254-B1 | ASYMETRIC HYDROGENATION OF BETA- or GAMMA-KETOESTERS AND BETA- or GAMMA-KETOAMIDES | MERCK & CO INC (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0770085-A1 | HETEROAROMATIC DIPHOSPHINES AS CHIRAL LIGANDS | ITALFARMACO SUD S.p.A. (IT) | 1997-05-02 | — | — | EP | disclosed |
| US-5596113-A | HYDROGENATION CATALYSTS | MERCK & CO., INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5508435-A | ASYMMETRIC REDUCTION WITH A RUTHENIUM CATALYST IN PRESENCE OF A STRONG ACID | MERCK & CO., INC. (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1996001831-A1 | HETEROAROMATIC DIPHOSPHINES AS CHIRAL LIGANDS | ITALFARMACO SUD S.P.A. (IT) | 1996-01-25 | — | — | WO | disclosed |
| WO-1995018784-A1 | ASYMETRIC HYDROGENATION OF β- or ηg-KETOESTERS AND β- or η-KETOAMIDES | MERCK & CO., INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| US-4973354-A | AGRICULTURE, OPTICAL ISOMERS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1990-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295798-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | SLC10A1, ERBB3, SLC10A2 | CHRM2 1846/4885CHRM4 1826/4885CHRM3 1142/4885 |
| US-20240376059-A1 | Compounds for the Treatment of Alzheimer's Disease | IAPP, GPR119, APP | CHRM2 77/4885CHRM4 76/4885CHRM3 47/4885 |
| US-11939302-B2 | Compounds for the treatment of Alzheimer's disease | IAPP, GPR119, APP | CHRM2 77/4885CHRM4 76/4885CHRM3 47/4885 |
| US-20230302162-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | PLA2G4B, PLA2G1B, PLA2G12B | CHRM2 3365/4885CHRM4 4050/4885CHRM3 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.